Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

University of Alberta

$40,000.00

Role of matrix metalloproteinase (MMP)-2 in regulating smooth muscle contraction

EF 2015-16

Résumé
Matrix metalloproteinases (MMPs) are proteins known to cause structural and functional changes in blood vessels by cutting other proteins into smaller pieces. MMP-2 is found in vascular smooth muscle and endothelial cells and has been studied for its important role in the regulation of vascular contraction. MMPs are produced without any activity and they need other proteins or oxidative stress to activate them. The Schulz lab was the first to show that MMP-2 is activated within cardiac cells by oxidative stress. Once activated, MMP-2 destroys proteins such as troponin and titin which are essential for normal heart muscle contraction. Thus we thought to test if there are similarly targeted contractile proteins in blood vessels which are susceptible to destruction by MMP-2 and if this affects the contraction of blood vessels. Calponin, smoothelin-B and smitin are contractile proteins found in smooth muscle cells which are structurally similar to troponin and titin. They help to maintain constriction and keep blood pressure normal. As troponin and titin are destroyed by MMP-2 in cardiac cells, calponin, smoothelin-B and smitin may be targets of MMP-2 in smooth muscle cells which may result in poor contractile function and low blood pressure. We showed that MMP-2 is activated in rat blood vessels during oxidative stress induced by bacterial toxins and that MMP inhibitor drugs improved vascular contraction in these rats. This led our lab to test if MMP-2 cleaves contractile proteins in vascular smooth muscle and contributes to the loss of contractile function. We wish to test in this proposal an exciting and novel concept that activated MMP-2 may destroy key proteins that control normal vascular smooth muscle contraction. This important idea may help us in the understanding of mechanisms involved in controlling blood pressure and new pharmacological approaches to regulate it.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
403045-2011
Name nom
Schulz, Richard
Department département
Pharmacology
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2011
Award amount
40000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
5504
Research subject group en
Animal biology
Research subject group fr
Biologie animale
Research subject en
Animal physiology and metabolism
Research subject fr
Physiologie et métabolisme des animaux
Partie
5
Nb partie
5
Application title
Role of matrix metalloproteinase (MMP)-2 in regulating smooth muscle contraction
Keyword
NSERC
Application summary
Matrix metalloproteinases (MMPs) are proteins known to cause structural and functional changes in blood vessels by cutting other proteins into smaller pieces. MMP-2 is found in vascular smooth muscle and endothelial cells and has been studied for its important role in the regulation of vascular contraction. MMPs are produced without any activity and they need other proteins or oxidative stress to activate them. The Schulz lab was the first to show that MMP-2 is activated within cardiac cells by oxidative stress. Once activated, MMP-2 destroys proteins such as troponin and titin which are essential for normal heart muscle contraction. Thus we thought to test if there are similarly targeted contractile proteins in blood vessels which are susceptible to destruction by MMP-2 and if this affects the contraction of blood vessels. Calponin, smoothelin-B and smitin are contractile proteins found in smooth muscle cells which are structurally similar to troponin and titin. They help to maintain constriction and keep blood pressure normal. As troponin and titin are destroyed by MMP-2 in cardiac cells, calponin, smoothelin-B and smitin may be targets of MMP-2 in smooth muscle cells which may result in poor contractile function and low blood pressure. We showed that MMP-2 is activated in rat blood vessels during oxidative stress induced by bacterial toxins and that MMP inhibitor drugs improved vascular contraction in these rats. This led our lab to test if MMP-2 cleaves contractile proteins in vascular smooth muscle and contributes to the loss of contractile function. We wish to test in this proposal an exciting and novel concept that activated MMP-2 may destroy key proteins that control normal vascular smooth muscle contraction. This important idea may help us in the understanding of mechanisms involved in controlling blood pressure and new pharmacological approaches to regulate it.